Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/22/2021 02/23/2021 02/24/2021 02/25/2021 02/26/2021 Date
157.58(c) 157.03(c) 155.02(c) 150.09(c) 151.11(c) Last
865 379 1 218 028 1 199 818 1 022 564 1 698 964 Volume
-0.11% -0.35% -1.28% -3.18% +0.68% Change
More quotes
Financials (USD)
Sales 2021 1 504 M - -
Net income 2021 -393 M - -
Net cash position 2021 2 025 M - -
P/E ratio 2021 -69,9x
Yield 2021 -
Sales 2022 2 273 M - -
Net income 2022 89,2 M - -
Net cash position 2022 2 456 M - -
P/E ratio 2022 351x
Yield 2022 -
Capitalization 27 376 M 27 376 M -
EV / Sales 2021 16,9x
EV / Sales 2022 11,0x
Nbr of Employees 2 092
Free-Float 99,4%
More Financials
Company
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV... 
Sector
Biotechnology & Medical Research
Calendar
03/01 | 02:40pmPresentation
More about the company
Notations Surperformance© of Seagen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SEAGEN INC.
02/24SEAGEN : to Present at the Cowen 41st Annual Healthcare Conference
BU
02/19ASTELLAS PHARMA : and Seagen Announce Submission of Two Supplemental Biologics L..
AQ
02/18INSIDER TRENDS : Seagen Insider Reports Option Conversion Extending 90-Day Buyin..
MT
02/18SEAGEN : Astellas Seek FDA Nod for Two Supplemental Applications For Cancer Drug
MT
02/18SEAGEN : and Astellas Announce Submission of Two Supplemental Biologics License ..
BU
02/16SEAGEN : RBC Capital Adjusts Seagen's Price Target to $169 From $186, Maintains ..
MT
02/15SEAGEN : European Commission Approves Seagen's TUKYSA for the Treatment of Patie..
AQ
02/15SEAGEN : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adva..
AQ
02/15ASTELLAS PHARMA : and Seagen Announce Presentation of Results from PADCEV Pivota..
AQ
02/12SEAGEN : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adva..
BU
02/12SEAGEN : and Astellas Announce Presentation of Results from PADCEV® (enfortumab ..
BU
02/12SEAGEN : Barclays Adjusts Seagen PT to $168 From $177, Maintains Equal Weight Ra..
MT
02/12SEAGEN : JP Morgan Adjusts Price Target for Seagen to $177 From $182, Maintains ..
MT
02/12SEAGEN : Goldman Sachs Adjusts Seagen's Price Target to $242 From $247, Maintain..
MT
02/12SEAGEN : Piper Sandler Adjusts Price Target on Seagen to $170 From $175, Maintai..
MT
More news
News in other languages on SEAGEN INC.
2020US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
2020SEAGEN INC. : Veröffentlichung des Quartalsergebnisses
2020SEAGEN INC. : publication des résultats trimestriels
202010 Biotechs qui font parler d'elles
2020Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 190,76 $
Last Close Price 151,11 $
Spread / Highest target 68,1%
Spread / Average Target 26,2%
Spread / Lowest Target -8,68%
EPS Revisions
Managers and Directors
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.-13.72%27 376
MODERNA, INC.48.19%61 888
LONZA GROUP AG0.88%46 924
IQVIA HOLDINGS INC.7.60%36 971
CELLTRION, INC.-17.13%35 993
HANGZHOU TIGERMED CONSULTING CO.,LTD-13.01%18 684